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Large observational trials and meta-analysis have confirmed the benefit of oral 
anticoagulation therapy (OACs), with the Vitamin K Antagonists (VKAs eg. warfarin) for 
stroke prevention in atrial fibrillation (AF), even in patients with ≥1 stroke risk factors using 
the CHA2DS2VASc score1. Indeed, the net clinical benefit (NCB) is positive for OAC use 
compared to no antithrombotic therapy or aspirin, even with 1 stroke risk factor – while the 
NCB is neutral or negative for aspirin compared to no antithrombotic therapy2.  The NCB is 
also higher as the CHA2DS2VASc score increases 3.  
There are some exceptions to these ‘general’ statements. Patients with stage 5 chronic kidney 
disease (CKD) or end stage renal failure on dialysis have been excluded from randomised 
trials, and such patients might have multiple risk factors for stroke and thus, high 
CHA2DS2VASc score4.  However, the balance between the risk and the benefits of oral 
anticoagulation (OAC) treatment for prevention of embolic events is less clear.  
Most stroke risk stratification approaches in AF have excluded patients with severe renal 
impairment and thus the benefit of OAC in patients with AF and normal renal function 
cannot be extrapolated to patients with AF in end stage renal failure (ESRF). The latter are 
high risk for thrombosis-related complications such as stroke, systemic thromboembolism, 
mortality and myocardial infarction, but paradoxically, these patients are also at risk of 
serious bleeding4.     
Many factors have been implicated to promote thrombogenicity along with the haemorrhagic 
tendency in AF patients with ESRF on renal replacement therapy (ie. haemodialysis or 
peritoneal dialysis). Abnormal renal function affects anticoagulation control5, and 
unsurprisingly, the management of such patients is extremely delicate6. CKD per se is 
associated with higher prevalence of AF and the numbers of dialysis patients are increasing7, 
the management dilemma for the optimal use of OAC in such patients is even more pressing.  
In the current issue of the Canadian Journal of Cardiology Harel et al8 provide a systematic 
review and meta-analysis regarding the safety and efficacy of Vitamin K antagonists (VKAs) 
for the prevention of ischaemic stroke in AF patients with end stage renal failure receiving 
dialysis (haemodiaysis and peritoneal dialysis). The total number of participants was 20,398 
of whom 4,779 (23%) were receiving warfarin. The primary outcome was defined as 
ischemic stroke or systemic thromboembolism, and secondary outcomes included intracranial 
haemorrhage (ICH), gastrointestinal bleeding (GIB) and all-cause mortality.  
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In the absence of any randomised control trials, 14 observational trials were included. There 
was a significant heterogeneity among the included studies regarding outcomes. For example, 
although transient ischaemic attack (TIA) is considered in most of the studies as a type of 
ischaemic stroke, in some this endpoint was not recorded. Also, the definition of bleeding 
varied from study to study.  Additionally, the authors were unable to perform meta-regression 
analysis due to paucity of available data for the majority of baseline characteristics apart from 
age. Despite the several limitations of this meta-analysis and systematic review, several high 
quality observational studies were included. The overall conclusion was that VKAs are not 
associated with any statistically significant difference in ischaemic stroke or ICH. There were 
more haemorrhagic events in the VKA group but that did not influence all cause mortality. 
There are no RCTs to support OAC therapy with VKAs for dialysis patients with AF.  
Among these patients are there subgroups with characteristics that might benefit from VKAs?   
An individualised approach, with careful assessment of the risks of ischaemic stroke against 
the risks of bleeding, will help management of patients who will benefit from OAC.    
There are important limitations to the metaanalysis by Harel et al. All the observational trials 
that conclude a non-beneficial role of VKA in patients with AF on dialysis did not report on 
quality of anticoagulation control, as reflected by time in therapeutic range (TTR).  On the 
contrary, 2 studies9,10 that demonstrated a reduced risk of thromboembolic events without a 
significant increase in haemorrhagic events in AF patients on dialysis have reported on the 
TTR. In these studies, the TTR was maintained in a reasonable level (54-60% or higher) and 
that was reflected in the findings. On the other hand, patients with poor OAC control have 
more bleeding and thromboembolic episodes 11.  
Many participants in the observational trials that were included in the meta-analysis by Harel 
et al, were also on antiplatelet drugs.  The concomitant use of antiplatelet drugs, NSAIDs and 
VKAs cumulatively increases the risk of bleeding. In the cases that triple or double 
antithrombotic therapy (VKA with aspirin and/or clopidogrel) is necessary, for example, 
following acute coronary syndromes, the optimal TTR should be above 70% to minimise 
bleeding complications. It is unclear why the antiplatetelet drugs were prescribed for these 
patients in the studies that were used in the systematic review by Harel et al8.  
Exposure to medications that can induce or enhance a bleeding diathesis, as well as excess 
alcohol intake, are additional modifiable risk factors for haemorrhagic events. Use of the 
HAS-BLED score is helpful to identify patients at high risk of bleeding who can be flagged 
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up for more regular review and followup, and to draw attention to the modifiable bleeding 
factors12 13.   The HAS-BLED score has been validated in patients on no antithrombotic 
therapy, aspirin and anticoagulants (warfarin and non-warfarin), as well as in AF and non-AF 
cohorts – thus would be applicable for all stages of the patient pathway. 
An observational study from Denmark 14 collected data from nationwide registries for 
patients with AF and CKD, and found that warfarin was associated with a significantly 
decreased risk of all-cause mortality (HR: 0.85, 95% CI: 0.72 to 0.99) in patients with end 
stage renal failure on dialysis. On the contrary, aspirin plus warfarin did not show any 
benefit. Fewer negative events, such as stroke or major haemorrhage, were observed in AF 
patients with high risk of stroke on peritoneal dialysis compared to patients with similar 
features but on haemodialysis.  
In another observational study on patients with peritoneal dialysis and AF, warfarin was 
associated with significantly reduced risk of ischaemic stroke without increasing the risk of 
intracranial haemorrhage15.  These findings suggest that the modality of dialysis is also 
important and might influence outcomes in these patients.  
For now, the VKAs appear to be the only OAC therapy with at least some studies to show 
clinical benefit for patients with AF and ESRF on dialysis. The Non-Vitamin K oral 
anticoagulants (NOACs) have been increasingly adopted for stroke prevention therapy in 
patients with non-valvular AF, given their increasing evidence of effectiveness and safety 
from trials and ‘real world’ use16 17,18.  The NOACs have a degree of renal excretion, and the 
absence of large trials in AF patients with creatinine clearance<25-30 ml/min makes 
clinicians doubt their use in ESRF.  Indeed, one study that assessed the outcomes of patients 
on haemodialysis with AF treated with dabigatran or rivaroxaban, found their use highly 
discouraging19. Apixaban has less renal excretion in its elimination pathway, compared to the 
other licenced NOACs, and in the USA label approved by the FDA, apixaban 5mg bid may 
be considered in AF patients undergoing haemodialysis even in the absence of trial outcome 
data. 
In conclusion, Harel et al8 provide a comprehensive systematic review and meta-analysis 
focused on the benefit-risk ratio of warfarin in patients with AF on dialysis, which not 
surprisingly, has similar findings with other previous meta-analysis of the same subject.  A 
well organised randomised control trial avoiding the heterogeneity pitfalls identified by the 
Harel et al would provide more precise evidence about the risk and benefit ratio of OAC in 
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dialysis (i.e haemodialysis vs peritoneal) patients with AF. For now, patients on dialysis with 
high risk of stroke (CHA2DS2VASc score ≥2) should be assessed individually and treated 
with warfarin with good TTR, unless there is a recent history of intracranial bleed or other 
major bleed4. The HAS-BLED score should also be routinely used to identify patients with 
high risk of bleeding who can be monitored and followed up more closely, and to address 
modifiable factors which contribute to bleeding.  Patient education, counselling and treatment 
adherence are also essential aspects of management20. 
Figure 1 provides a suggested approach for the management of such AF patients with end 
stage renal disease on dialysis who are being considered for thrombopropylaxis.  
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Abbreviations: CHA2DS2VASc : C, congestive heart failure, H, hypertension, A2,age at least 
75 years (x2), D, diabetes, S2, previous stroke, TIA, or systemic embolism, ( x2)  V, vascular 
disease, A, age 65 through 74 years, Sc, sex category female sex. HAS-BLED: H, 
Hypertension, A, Abnormal renal and liver function, S, Stroke, B, Bleeding tendency, L, 
Labile INRs, E, Elderly, D, Drugs. 
 
 
Figure 1. Suggested management approach for using oral anticoagulation therapy in 
patients with Atrial fibrillation and end stage renal failure  
 
Patients with Atrial Fibrillation and End Stage Renal Failure 
(creatinine clearance <15 ml/min) on Renal Replacement 
therapy (haemodialysis or peritoneal dialysis) 
Arrange extra review and follow 
up for patients with HASBLED ≥3 , 
and to ensure satisfactory Time in 
Therapeutic Range[TTR] (>65%), 
or in patients with HASBLED<3 
but with TTR<65%. 
Avoid anticoagulation in patients 
with recent history of intracranial 
haemorrhage or gastrointestinal 
bleed (if the primary cause is not 
corrected) and consider alternative 
measures eg. left atrial appendage 
closure device in patients at high 
risk for stroke  
Assess risk of bleeding using 
HASBLED score 
Assess risk of score with  
CHA2DS2VASc score 
Use HASBLED score to ‘flag up’ patients at high 
risk (score ≥3), and to address modifiable 
bleeding risk factors  
(i.e. uncontrolled blood pressure, concomitant 
antiplatelet drugs/NSAIDs, alcohol excess, etc) 
If CHA2DS2VASc ≥2  
consider initiating VKA,  
aim for TTR >65-70% 
